Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $33.2 Million - $39.1 Million
-150,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $1.77 Million - $2.23 Million
10,000 Added 7.14%
150,000 $32.9 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $25.1 Million - $28 Million
-138,130 Reduced 49.66%
140,000 $25.4 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $1.64 Million - $1.93 Million
8,730 Added 3.24%
278,130 $56.1 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $26.5 Million - $30.9 Million
128,100 Added 90.66%
269,400 $57.9 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $9.9 Million - $13.2 Million
47,800 Added 51.12%
141,300 $33.4 Million
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $3.96 Million - $4.7 Million
15,500 Added 19.87%
93,500 $25.4 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $450,960 - $591,600
-2,000 Reduced 2.5%
78,000 $22.6 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $41.5 Million - $51.5 Million
-207,900 Reduced 72.21%
80,000 $19 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $21.3 Million - $28.6 Million
127,900 Added 79.94%
287,900 $63 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $2.66 Million - $2.99 Million
16,000 Added 11.11%
160,000 $27.1 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $1.89 Million - $2.19 Million
11,500 Added 8.68%
144,000 $26.4 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $3.68 Million - $4.38 Million
-22,500 Reduced 14.52%
132,500 $24.4 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $23.5 Million - $29.8 Million
155,000 New
155,000 $25.7 Million
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $31 Million - $35.6 Million
-184,800 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $26.9 Million - $31.4 Million
184,800 New
184,800 $31.4 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Melqart Asset Management (Uk) LTD Portfolio

Follow Melqart Asset Management (Uk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Melqart Asset Management (Uk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Melqart Asset Management (Uk) LTD with notifications on news.